Dr. Victor Sandor was appointed to AbCellera's Board of Directors on June 1, 2026 as an independent director. He has more than 20 years of experience in the pharmaceutical and biotechnology industries and was most recently Chief Medical Officer at Array BioPharma prior to its acquisition by Pfizer, where he was instrumental in the approvals of Braftovi (encorafenib) and Mektovi (binimetinib). He previously held senior clinical-development roles at Incyte Corporation, Biogen and AstraZeneca, and serves on the boards of ADC Therapeutics, Kymera Therapeutics and Prelude Therapeutics. He received his M.D.C.M. from McGill University and completed a fellowship in medical oncology at the U.S. National Institutes of Health. (Source: abcellera.com)